Cancer and Thrombosis: New Treatments, New Challenges

The direct-acting oral anticoagulant (DOAC) has become an alternative to low-molecular-weight heparin (LMWH) for treatment and prophylaxis of venous thromboembolism (VTE) in cancer patients. The clinicians are, however, faced with difficult decisions regarding DOAC treatment: Which patients cannot u...

Descripción completa

Detalles Bibliográficos
Autor principal: Dahm, Anders Erik Astrup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293316/
https://www.ncbi.nlm.nih.gov/pubmed/34204957
http://dx.doi.org/10.3390/medsci9020041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293316/
https://www.ncbi.nlm.nih.gov/pubmed/34204957
http://dx.doi.org/10.3390/medsci9020041

Ejemplares similares